TROG Cancer Research
Members Login   CQMS Login

Our partner: GenesisCare

GenesisCare & TROG's strategic partnership is an important step toward patient access to clinical trials




GenesisCare and the Trans-Tasman Radiation Oncology Group (TROG) have formed a strategic partnership where all 23 Genesis CancerCare centres become members of the TROG Facility Alliance.

This is the first alliance of this scale in Australia and significantly advances the continuation and expansion of cancer research.

For almost 30 years TROG Cancer Research has been a leader a global leader in radiotherapy research conducting more than 100 clinical trials involving over 14,500 patient volunteers to help advance cancer treatments. 

GenesisCare is the leading provider of radiation oncology in Australia undertaking around 320,000 cancer treatments every year.

GenesisCare and TROG will work together to improve patient access to clinical trials and promote innovation in research to deliver better patient outcomes. It will become easier for doctors and patients across Australia to access the latest information on treatment techniques and the best standards of care.

Genesis CancerCare centres will have access to the full benefits of the TROG Facility Alliance Program including: 

  • TROG centralised information technology infrastructure designed to streamline and facilitate clinical trial participation
  • Independent quality assurance
  • Good Clinical Practice Training Modules
  • Clinical Trial activation kits for new centres
  • Staff training opportunities at the TROG Central Operations Office
  • Authorship for high accruing centres on TROG manuscripts
  • Full or Affiliate membership to TROG Cancer Research
  • Access to TROG web-site Membership area
  • Site visits to Genesis Centres across Australia from TROG staff
  • Credentialing of GenesisCare Radiation Therapy Centres

Professor David Christie, a radiation oncologist from GenesisCare in Queensland, said “This partnership demonstrates GenesisCare’s commitment to supporting research across the GenesisCare network and the industry more broadly”.

Dan Collins, Managing Director, GenesisCare, added “Our partnership with TROG is the next stage in how GenesisCare can actively drive the delivery of advanced, high quality care for Australians who have cancer. Our doctors and staff already share a passion for research and the latest clinical practice; by focusing more resources on evidenced based research with TROG we believe cancer patients will get better outcomes.


About GenesisCare

GenesisCare is Australia's largest provider of radiation oncology, cardiology and sleep treatments.

With more than 1400 employees, GenesisCare provides essential health care services across more than 120 sites and clinics ranging from the major capital cities to regional and rural centres.

GenesisCare exists to fill the treatment gap for the biggest disease burdens in Australia — cancer and cardiovascular disease — in an environment of substantial unmet need from an ageing population.

GenesisCare is currently involved in or leading more than 120 clinical trials. The group uses its national network to coordinate and share clinical information and know-how, helping inform future approaches to treatment and care.

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.